The 2023 data showcases varied consumption of Peptic Ulcer and GORD medicines, with the Netherlands leading at 134.9 daily doses per thousand persons. Countries like Portugal (114.6) and New Zealand (109.0) follow. Most countries experienced a positive year-on-year growth, like Croatia (6.44%) and Estonia (5.7%), indicating increasing demand, except Australia, which saw a decrease of 4.36%. Over the last five years, these metrics suggest a continuous global rise, driven likely by lifestyle factors and increased diagnosis rates.
Future trends may underscore advancements in treatment options, an aging population's rising healthcare needs, and possible shifts in drug regulation impacting sales and consumption patterns globally.
Top countries in Peptic Ulcer and Gastro-Oesophageal Reflux Diseases (GORD) Medicine Use by Country
| # | 10 Countries | Units (Defined Daily Dosage) Per Thousand Persons Per Day | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Netherlands | 134.9 | 2023 | +2.51% | +1.31% | View data |
| 2 | 2 Portugal | 114.6 | 2023 | +2.41% | +4.22% | View data |
| 3 | 3 New Zealand | 109 | 2023 | -1.09% | View data | |
| 4 | 4 Belgium | 107.6 | 2023 | +2.28% | +2.05% | View data |
| 5 | 5 Greece | 94 | 2023 | +3.41% | +4.7% | View data |
| 6 | 6 Slovenia | 87.2 | 2023 | +4.06% | +4.46% | View data |
| 7 | 7 Czech Republic | 84 | 2023 | +1.69% | +2.27% | View data |
| 8 | 8 Italy | 82.9 | 2023 | -0.72% | +1.38% | View data |
| 9 | 9 Croatia | 82.4 | 2023 | +4.3% | +6.44% | View data |
| 10 | 10 Norway | 79.2 | 2023 | +2.99% | +3.31% | View data |
